ArticleOncotarget2017
CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasion.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Potential of Selected C-X-C Motif Chemokines as Biomarkers in Colorectal Cancer Diagnosis.International journal of molecular sciences · 2025Review
- The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.Cellular & molecular biology letters · 2024Review
- Impact of Fetal Exposure to Endocrine Disrupting Chemical Mixtures on FOXA3 Gene and Protein Expression in Adult Rat Testes.International journal of molecular sciences · 2023Article
- Osteoid cell-derived chemokines drive bone-metastatic prostate cancer.Frontiers in oncology · 2023Review
- Identification of necroptosis-related subtypes, development of a novel signature, and characterization of immune infiltration in colorectal cancer.Frontiers in immunology · 2022Article
- CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities.Life (Basel, Switzerland) · 2021Review
- IL-16 and BCA-1 Serum Levels Are Associated with Disease Severity ofPathogens (Basel, Switzerland) · 2021Article
- Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.Scientific reports · 2021Article
- The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature.International journal of molecular sciences · 2021Review
- CXCL13 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021Review
- CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer.Cancer research and treatment · 2020Article
- Duality of B Cell-CXCL13 Axis in Tumor Immunology.Frontiers in immunology · 2020Review
- Gastric Damage and Cancer-Associated Biomarkers inFrontiers in microbiology · 2020Review
- Identification of important invasion and proliferation related genes in adrenocortical carcinoma.Medical oncology (Northwood, London, England) · 2019Article
- CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond.Frontiers in endocrinology · 2019Review
- Regulative role of the CXCL13-CXCR5 axis in the tumor microenvironment.Precision clinical medicine · 2018Review
- Translational Research for Identifying Potential Early-stage Prostate Cancer Biomarkers.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Androgen receptor (AR) is a key transcription factor playing a critical role in prostate cancer (PCa) initiation and progression. However, the molecular mechanisms of AR action in prostate cancer are not very clear. CXCL13, known as B cell attracting chemokine1 (BCA-1), is a member of CXC chemokine family and relevant to cancer metastasis. This study shows that CXCL13 is an androgen-responsive gene and involved in AR-induced PCa cell migration and invasion. In clinical specimens, expression of CXCL13 in PCa tissues is markedly higher than that in adjacent normal tissues. In cultures, expression of CXCL13 is up-regulated by androgen-AR axis at both mRNA and protein levels. Furthermore, Chip-Seq assay identifies canonical androgen responsive elements (ARE) at CXCL13 enhancer and dual-luciferase reporter assays reveals that the ARE is highly responsive to androgen while mutations of the ARE abolish the reporter activity. Additional chromatin immunoprecipitation (ChIP) assays also identify that the ARE presents androgen responsiveness. In addition, CXCL13 promotes G2/M phase transition by increasing Cyclin B1 levels in PCa cells. Functional studies demonstrate that reducing endogenous CXCL13 expression in LNCaP cells largely weakens androgen-AR axis induced cell migration and invasion. Taken together, our study implicates for the first time that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.